Latest News

Photon-counting computed tomography (PCCT) is a foundational cornerstone that can facilitate detection, targeting and reversal of coronary artery disease.

In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses pertinent principles, pearls and outcomes with Y90 radioembolization for the treatment of patients with liver cancer.

Researchers found that former NFL players had a 3.8-fold higher mortality rate for all-cause dementia and a nearly 3.9-fold higher mortality rate for Parkinson’s disease, according to a study involving over 19,800 former NFL players.

The Alturion ultrasound device reportedly combines portability, AI-enhanced capabilities and a user-friendly interface to facilitate streamlined workflows.

Deep learning-based motion correction with the CLEAR Motion software reportedly bolsters cardiac imaging quality while the PIQE 1024 Deep Learning Reconstruction software offers equivalent SNR to photon-counting CT for high-resolution views of objects less than 0.5 mm.

Researchers said the combination of 18F-flotufolastat PET/MRI may lead to a 57 percent reduction of prostate biopsies in comparison to a 25 percent reduction with prostate MRI alone.

The newly FDA-cleared PACS Viewer from CliniComp reportedly allows direct review and analysis of imaging within a patient’s chart.

In a recent interview, Nina Kottler, MD, offered her perspective on findings from a recent report on AI in health care, AI integration challenges and what the future holds with AI in radiology.

In comparison to everolimus, the peptide receptor radionuclide therapy (177Lu)Lu-edotreotide provided over a nine month longer median progression-free survival for patients with gastroenteropancreatic neuroendocrine tumours (GEP NETs), according to new phase 3 research.

Catch up on the top radiology content of the past week.

For patients with known or suspected neuroendocrine tumors, the radiopharmaceutical 64Cu-SARTATE offered over 50 percent higher average detection of liver foci than 68Ga-DOTATATE at four hours and 20 hours post-injection, according to research presented at the recent SNMMI conference.

In a recent interview, Amy Patel, MD, discussed recent research on breast cancer screening, pertinent obstacles and keys to facilitating improved adherence with mammography screening.

While acknowledging key limitations, the authors of a new literature review noted that contrast-enhanced mammography offers a viable alternative to conventional imaging and breast MRI for preoperative tumor evaluation and may have a significant impact on surgical management.